Patents by Inventor Lawrence M. Kauvar

Lawrence M. Kauvar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
    Patent number: 10639370
    Abstract: Antibodies, compositions and methods are provided for treatment and prophylaxis of influenza virus. Antibodies and antigen-binding fragments are provided that bind near the HA0 maturation cleavage site consensus sequence of influenza hemagglutinin A. Antibody compositions, combinations and methods for effective passive immunization across influenza A and B strains are also provided.
    Type: Grant
    Filed: February 4, 2015
    Date of Patent: May 5, 2020
    Assignees: CONTRAFECT CORPORATION, TRELLIS BIOSCIENCE, LLC
    Inventors: Angeles Estelles, Lawrence M. Kauvar, Adam Vigil, Michael Wittekind
  • Drug regimen for treatment of cerebral ischemia
    Patent number: 10617756
    Abstract: Treatment of subjects experiencing cerebral ischemia is improved when the treatment employs a thrombolytic and an inhibitor against vascular endothelial growth factor receptor signal transduction (VEGF-RST) at a reduced, low dosage compared to that used to treat cancer patients. The treatment is also improved to permit point-of-care use by formulating protein drugs for long term stability at room temperature, providing doses appropriate for the method, and by combining the therapeutic agents with a point-of-care diagnostic for blood brain barrier integrity.
    Type: Grant
    Filed: December 29, 2017
    Date of Patent: April 14, 2020
    Assignee: Shimojani, LLC
    Inventors: Lawrence M. Kauvar, Damir Janigro
  • Binding moieties for biofilm remediation
    Patent number: 10570193
    Abstract: Binding agents able to disrupt bacterial biofilms of diverse origin are described, including monoclonal antibodies suitable for administration to a selected species, and antibody mimics including aptamer nucleic acids. Methods to prevent formation of or to dissolve biofilms with these binding agents are also described. Immunogens for eliciting antibodies to disrupt biofilms are also described.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: February 25, 2020
    Assignee: Trellis Bioscience, LLC
    Inventors: Lawrence M. Kauvar, Stefan Ryser, Angeles Estelles, Reyna J. Simon, Lauren Opremcak Bakaletz, Steven David Goodman
  • ANTIBODIES USEFUL IN PASSIVE INFLUENZA IMMUNIZATION, AND COMPOSITIONS, COMBINATIONS AND METHODS FOR USE THEREOF
    Publication number: 20200054749
    Abstract: Antibodies, compositions and methods are provided for treatment and prophylaxis of influenza virus. Antibodies and antigen-binding fragments are provided that hind near the HA0 maturation cleavage site consensus sequence of influenza hemagglutinin A. Antibody compositions, combinations and methods for effective passive immunization across influenza A and B strains are also provided.
    Type: Application
    Filed: November 5, 2019
    Publication date: February 20, 2020
    Inventors: Angeles Estelles, Lawrence M. Kauvar, Adam Vigil, Michael Wittekind
  • CONFORMATIONAL EPITOPES IN RESPIRATORY SYNCYTIAL VIRUS G PROTEIN CENTRAL CONSERVED REGION
    Publication number: 20190135876
    Abstract: X-ray crystallography has defined conformational properties of a key functional region of the G protein of respiratory syncytial virus (RSV). Mimics of these epitopes have utility as immunogens, as tools for discovery of antibodies and other monoclonal binding agents, and as pharmacological agents to modulate activity of the host receptors for this viral protein.
    Type: Application
    Filed: October 12, 2018
    Publication date: May 9, 2019
    Applicants: Trellis Bioscience, LLC, The Regents of the University of California
    Inventors: Rebecca DUBOIS, Stas FEDECHKIN, Lawrence M. KAUVAR
  • Binding moieties for biofilm remediation
    Patent number: 10233234
    Abstract: Binding agents able to disrupt bacterial biofilms of diverse origin are described, including monoclonal antibodies suitable for administration to a selected species, and antibody mimics including aptamer nucleic acids. Methods to prevent formation of or to dissolve biofilms with these binding agents are also described. Immunogens for eliciting antibodies to disrupt biofilms are also described.
    Type: Grant
    Filed: May 2, 2016
    Date of Patent: March 19, 2019
    Assignee: Trellis Bioscience, LLC
    Inventors: Lawrence M. Kauvar, Stefan Ryser, Angeles Estelles, Reyna J. Simon, Lauren Opremcak Bakaletz, Steven David Goodman
  • BINDING MOIETIES FOR BIOFILM REMEDIATION
    Publication number: 20190055304
    Abstract: Binding agents able to disrupt bacterial biofilms of diverse origin are described, including monoclonal antibodies suitable for administration to a selected species, and antibody mimics including aptamer nucleic acids. Methods to prevent formation of or to dissolve biofilms with these binding agents are also described. Immunogens for eliciting antibodies to disrupt biofilms are also described.
    Type: Application
    Filed: November 5, 2018
    Publication date: February 21, 2019
    Applicant: Trellis Bioscience, LLC
    Inventors: Lawrence M. KAUVAR, Stefan RYSER, Angeles ESTELLES, Reyna J. SIMON, Lauren Opremcak BAKALETZ, Steven David GOODMAN
  • High affinity human antibodies to human cytomegalovirus (CMV) gB protein
    Patent number: 10030069
    Abstract: Recombinant monoclonal antibodies to human cytomegalovirus (CMV) gB protein are described. The affinities of these antibodies are higher than the best previously reported antibodies. Since high affinity is critical to prevention of virus transfer across the placenta, the invention antibodies are useful as therapeutic and prophylactic agents to prevent or ameliorate effects on the fetus of CMV infection during pregnancy.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: July 24, 2018
    Assignee: Trellis Bioscience, LLC
    Inventors: Lawrence M. Kauvar, Stote Ellsworth, William Usinger, Krista Maureen McCutcheon, Ying-Ping Jiang, Fen Zhang, Bo Chen, Gizette Sperinde, Minha Park, Orit Foord
  • DRUG REGIMEN FOR TREATMENT OF CEREBRAL ISCHEMIA
    Publication number: 20180185475
    Abstract: Treatment of subjects experiencing cerebral ischemia is improved when the treatment employs a thrombolytic and an inhibitor against vascular endothelial growth factor receptor signal transduction (VEGF-RST) at a reduced, low dosage compared to that used to treat cancer patients. The treatment is also improved to permit point-of-care use by formulating protein drugs for long term stability at room temperature, providing doses appropriate for the method, and by combining the therapeutic agents with a point-of-care diagnostic for blood brain barrier integrity.
    Type: Application
    Filed: December 29, 2017
    Publication date: July 5, 2018
    Applicant: Shimojani, LLC
    Inventors: Lawrence M. KAUVAR, Damir JANIGRO
  • NATIVE HUMAN ANTIBODIES FOR IMMUNE CHECKPOINT MODULATION TARGETS TIM-3 AND B7-H3
    Publication number: 20180186880
    Abstract: Novel monoclonal antibodies directed against immune checkpoint modulator (ICM) proteins TIM-3 and B7-H3 are useful in treating cancer and immune system disorders.
    Type: Application
    Filed: January 3, 2018
    Publication date: July 5, 2018
    Applicant: Trellis Bioscience, LLC
    Inventors: Angeles ESTELLES, Mikhail GISHIZKY, Stefan RYSER, Lawrence M. KAUVAR
  • Diagnostic marker for treatment of cerebral ischemia
    Patent number: 9913899
    Abstract: Identification of candidates for treatment and treatment of subjects experiencing cerebral ischemia wherein the treatment employs a thrombolytic or thrombectomy agent and an inhibitor of vascular endothelial growth factor (VEGF) receptor-mediated signal transduction are determined by testing the blood of a patient for total S-100B or for S-100BB as a marker of blood brain barrier integrity.
    Type: Grant
    Filed: March 13, 2015
    Date of Patent: March 13, 2018
    Assignee: Shimojani, LLC
    Inventors: Lawrence M. Kauvar, Damir Janigro
  • MONOCLONAL ANTIBODIES TARGETING KILLER IMMUNOGLOBULIN-LIKE RECEPTOR (KIR) FAMILY SIGNALING
    Publication number: 20180002420
    Abstract: Monoclonal antibodies derived from the native human repertoire that bind the extracellular portion of Killer IgG Receptor (KIR) and pharmaceutical and veterinary compositions thereof are useful in treating cancer in human and other subjects.
    Type: Application
    Filed: June 9, 2017
    Publication date: January 4, 2018
    Applicant: Trellis Bioscience, LLC
    Inventors: Angeles ESTELLES, Mikhail GISHIZKY, Stefan RYSER, Lawrence M. KAUVAR
  • HIGH AFFINITY HUMAN ANTIBODIES TO HUMAN CYTOMEGALOVIRUS (CMV) GB PROTEIN
    Publication number: 20170204165
    Abstract: Recombinant monoclonal antibodies to human cytomegalovirus (CMV) gB protein are described. The affinities of these antibodies are higher than the best previously reported antibodies. Since high affinity is critical to prevention of virus transfer across the placenta, the invention antibodies are useful as therapeutic and prophylactic agents to prevent or ameliorate effects on the fetus of CMV infection during pregnancy.
    Type: Application
    Filed: March 20, 2017
    Publication date: July 20, 2017
    Applicant: Trellis Bioscience, LLC
    Inventors: Lawrence M. KAUVAR, Stote ELLSWORTH, William USINGER, Krista Maureen MCCUTCHEON, Ying-Ping JIANG, Fen ZHANG, Bo CHEN, Gizette SPERINDE, Minha PARK, Orit FOORD
  • ANTIBODIES USEFUL IN PASSIVE INFLUENZA IMMUNIZATION, AND COMPOSITIONS, COMBINATIONS AND METHODS FOR USE THEREOF
    Publication number: 20170189529
    Abstract: Antibodies, compositions and methods are provided for treatment and prophylaxis of influenza virus. Antibodies and antigen-binding fragments are provided that bind near the HA0 maturation cleavage site consensus sequence of influenza hemagglutinin A. Antibody compositions, combinations and methods for effective passive immunization across influenza A and B strains are also provided.
    Type: Application
    Filed: February 4, 2015
    Publication date: July 6, 2017
    Inventors: Angeles Estelles, Lawrence M. Kauvar, Adam Vigil, Michael Wittekind
  • High affinity human antibodies to human cytomegalovirus (CMV) GB protein
    Patent number: 9688744
    Abstract: Recombinant monoclonal antibodies to human cytomegalovirus (CMV) gB protein are described. The affinities of these antibodies are higher than the best previously reported antibodies. Since high affinity is critical to prevention of virus transfer across the placenta, the invention antibodies are useful as therapeutic and prophylactic agents to prevent or ameliorate effects on the fetus of CMV infection during pregnancy.
    Type: Grant
    Filed: April 27, 2015
    Date of Patent: June 27, 2017
    Assignee: Trellis Bioscience, LLC
    Inventors: Lawrence M. Kauvar, Stote Ellsworth, William Usinger, Krista Maureen McCutcheon, Ying-Ping Jiang, Fen Zhang, Bo Chen, Gizette Sperinde, Minha Park, Orit Foord
  • Pharmaceutical composition for treating ischemic events
    Patent number: 9439961
    Abstract: Methods and pharmaceutical compositions for treating severe ischemic events including cerebral infarction, cardiac infarction, or pulmonary embolism, comprising a thrombolytic intervention including thrombolytic agents and an inhibitor of vascular endothelial growth factor (VEGF) receptor-mediated signal transduction are disclosed.
    Type: Grant
    Filed: January 9, 2014
    Date of Patent: September 13, 2016
    Assignee: NIIGATA UNIVERSITY
    Inventors: Takayoshi Shimohata, Lawrence M. Kauvar
  • BINDING MOIETIES FOR BIOFILM REMEDIATION
    Publication number: 20160237145
    Abstract: Binding agents able to disrupt bacterial biofilms of diverse origin are described, including monoclonal antibodies suitable for administration to a selected species, and antibody mimics including aptamer nucleic acids. Methods to prevent formation of or to dissolve biofilms with these binding agents are also described. Immunogens for eliciting antibodies to disrupt biofilms are also described.
    Type: Application
    Filed: May 2, 2016
    Publication date: August 18, 2016
    Applicant: Trellis Bioscience, LLC
    Inventors: Lawrence M. KAUVAR, Stefan RYSER, Angeles ESTELLES, Reyna J. SIMON
  • Antibodies immunoreactive with heregulin-coupled HER3
    Patent number: 9321839
    Abstract: Recombinant materials and methods for producing antibodies that specifically bind heregulin-coupled HER3, at a site distinct from the heregulin binding site, are described. These antibodies are particularly useful in treating cancer that expresses HER3.
    Type: Grant
    Filed: September 2, 2014
    Date of Patent: April 26, 2016
    Assignee: TRELLIS BIOSCIENCE, LLC
    Inventors: Bruce Keyt, Lawrence M. Kauvar, Ellen J. Collarini, Orit Foord, Gizette Sperinde, Marjan Fatholahi, Hung Nguyen
  • Anti-RSV G protein antibodies
    Patent number: 9321830
    Abstract: Individual monoclonal antibodies and fragments that bind a conserved epitope of the G protein of RSV and which are minimally immunogenic when administered to a human subject, are useful in treating RSV infections.
    Type: Grant
    Filed: September 25, 2012
    Date of Patent: April 26, 2016
    Assignee: Trellis RSV Holdings, Inc.
    Inventors: Lawrence M. Kauvar, Ellen J. Collarini, Bruce Keyt, Orit Foord
  • BINDING MOIETIES FOR BIOFILM REMEDIATION
    Publication number: 20150299298
    Abstract: Binding agents able to disrupt bacterial biofilms of diverse origin are described, including monoclonal antibodies suitable for administration to a selected species and decoy nucleic acids. Methods to prevent formation of or to dissolve biofilms with these binding agents are also described. Immunogens for eliciting antibodies to disrupt biofilms are also described.
    Type: Application
    Filed: July 1, 2015
    Publication date: October 22, 2015
    Inventors: Lawrence M. KAUVAR, Stefan RYSER, Angeles ESTELLES, Robert STEPHENSON, Reyna J. SIMON, Omar NOURZAIE